文献速递妇科肿瘤

卵巢癌同源重组缺陷检测的标准化:MITO16A/MaNGO-OV2试验结果

Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
PubMed 文献 · Eur J Cancer · 2024-05-23

该研究在100例未经治疗的卵巢癌患者甲醛固定石蜡包埋肿瘤样本中,将三种商业panel(TruSight Oncology 500 HRD、Oncomine Comprehensive Assay Plus、SOPHiA DDM HRD solution)与Myriad参考检测的HRD状态进行对比,结果显示三种商业panel在BRCA突变状态、基因组不稳定值和HRD状态三个层面均与参考方法具有良好一致性,且与临床结局的关联趋势与Myriad相似。

要点

  • 三种商业panel与Myriad参考检测在HRD状态上的一致性为90.4%至97.6%。
  • BRCA突变状态一致性为94.4%至97.7%,基因组不稳定值一致性为88.2%至95.3%。
  • 三种商业panel均观察到HRD阳性患者缓解率、无进展生存和总生存的获益趋势,与Myriad相似。

核心结论

  • 数据表明商业检测用于评估HRD状态具有可行性,与参考方法一致性良好且与临床结局相关。

研究设计与样本

  • 对100例未经治疗的卵巢癌患者甲醛固定石蜡包埋肿瘤样本DNA进行HRD分析,Myriad检测结果已可得,使用TruSight Oncology 500 HRD assay(Illumina)、Oncomine Comprehensive Assay Plus(Thermo Fisher Scientific)和SOPHiA DDM HRD solution panel(SOPHiA Genetics)三种商业panel进行检测。

主要发现

  • 与参考方法相比,BRCA突变状态一致性为94.4%至97.7%。
  • 基因组不稳定值一致性为88.2%至95.3%。
  • HRD状态一致性为90.4%至97.6%。
  • 三种商业panel均观察到HRD阳性患者缓解率、无进展生存和总生存的获益趋势,与Myriad相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homologous Recombination Deficiency (HRD) status predicts response to treatment with poly(ADP-ribose) polymerase inhibitors in Ovarian Cancer (OC) patients. The Myriad myChoiceCDx Assay is approved by Food and Drug Agency for the HRD assessment. Here we compared the HRD status obtained by three commercial panels with the results from Myriad reference test. METHODS: The HRD analysis was performed on DNA from formalin-fixed and paraffin-embedded tumor samples of 100 untreated OC patients for which Myriad assay results were available, using TruSight Oncology 500 HRD assay (Illumina), Oncomine Comprehensive Assay Plus (Thermo Fisher Scientific) and SOPHiA DDM HRD solution panel (SOPHiA Genetics). RESULTS: A good overall concordance with the reference method was demonstrated at three different levels: BRCA mutational status (from 94.4 % to 97.7 %), the genomic instability value (from 88.2 % to 95.3 %) and for the HRD status (from 90.4 % to 97.6 %). Moreover, a trend in favour of HRD positive patients for response rate, progression-free survival and overall survival similar to Myriad was observed for all three tests. DISCUSSION: Our data suggest the feasibility of commercial testing for assessing HRD status, with a good concordance with the reference method and association with clinical outcome.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roma C, Esposito Abate R, Sacco A, et al. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial. Eur J Cancer. 2024. PMID: 38797038. doi:10.1016/j.ejca.2024.114127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。